Authors
Teguh Hafiz Ambar Wibawa, Hendris Wongso, Tita Puspitasari, Alfian Mahardika Forentin, Tursino, Muhayatun Santoso, Daryono Hadi Tjahjono
Published in
RSC advances. Jul 17, 2026. Epub Jul 17, 2026.
Abstract
Benzothiazole derivatives have attracted attention for radiopharmaceutical development due to their potential interactions with biological targets associated with breast cancer. In the present study, a novel 99mTc-DTPA-benzothiazole-17 (TDB-17) compound was synthesized, radiolabeled, and preliminarily evaluated for breast cancer imaging research. In silico studies were performed to predict the interaction of the benzothiazole derivative with breast cancer-related biological targets. TDB-17 was synthesized by conjugating 2-aminobenzothiazole with CaNa3-DTPA and subsequently radiolabeled with 99mTc using SnCl2 as a reducing agent. The synthesized compound and radiocomplex were characterized using radio-high-performance liquid chromatography (radio-HPLC), high-resolution mass spectrometry (HRMS), and nuclear magnetic resonance (NMR). The radiolabeling process produced a radiochemical purity of 96.2 ± 1.2%. A preliminary biological evaluation showed that TDB-17 exhibited hydrophilic properties (log P = -1.5 ± 0.2) and time-dependent cellular uptake in MCF-7 cells, reaching 78.4% at 120 min. Biodistribution and gamma-camera imaging studies in normal mice showed predominant accumulation of TDB-17 in the liver, lungs, and spleen, providing initial information on the in vivo distribution of the radiocomplex. Overall, TDB-17 demonstrated favorable radiochemical characteristics and a preliminary biological profile, supporting further investigation of this 99mTc-labeled benzothiazole derivative for breast cancer imaging applications.
PMID:
42555439
Bibliographic data and abstract were imported from PubMed on 06 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0